{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T09:15:37Z","timestamp":1775726137466,"version":"3.50.1"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.ejmech.2023.115267","type":"journal-article","created":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T20:42:54Z","timestamp":1678480974000},"page":"115267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Discovery of orally effective and safe GPR40 agonists by incorporating a chiral, rigid and polar sulfoxide into \u03b2-position to the carboxylic acid"],"prefix":"10.1016","volume":"251","author":[{"given":"Cheng","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi-Meng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanjun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"He","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huxin","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhikan","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Qiu","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115267_bib2","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nrd2782","article-title":"Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes (Reprinted from Nature Reviews Drug Discovery","volume":"8","author":"Ahren","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115267_bib3","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nature01478","article-title":"Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40","volume":"422","author":"Itoh","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115267_bib4","doi-asserted-by":"crossref","first-page":"11303","DOI":"10.1074\/jbc.M211495200","article-title":"The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids","volume":"278","author":"Briscoe","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115267_bib5","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/dom.12442","article-title":"GPR40 agonists for the treatment of type 2 diabetes: life after 'TAKing' a hit","volume":"17","author":"Mancini","year":"2015","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejmech.2023.115267_bib6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2014.10.002","article-title":"GPR40 (FFAR1) - combined Gs and Gq signaling invitro is associated with robust incretin secretagogue action exvivo and invivo","volume":"4","author":"Hauge","year":"2015","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.ejmech.2023.115267_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046300","article-title":"A potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents","volume":"7","author":"Luo","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2023.115267_bib8","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/nrd.2015.4","article-title":"G protein-coupled receptors as targets for anti-diabetic therapeutics","volume":"15","author":"Oh","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115267_bib9","doi-asserted-by":"crossref","first-page":"5603","DOI":"10.1016\/j.bmcl.2016.10.074","article-title":"GPR40 agonists for the treatment of type 2 diabetes mellitus: the biological characteristics and the chemical space","volume":"26","author":"Chen","year":"2016","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2023.115267_bib10","doi-asserted-by":"crossref","first-page":"736","DOI":"10.6023\/cjoc201511011","article-title":"Advances in small-molecule GPR40 agonists for treatment of type 2 diabetes mellitus","volume":"36","author":"Li","year":"2016","journal-title":"Chin. J. Org. Chem."},{"key":"10.1016\/j.ejmech.2023.115267_bib11","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1016\/j.bmcl.2014.05.019","article-title":"Recent developments in the discovery of FFA1 receptor agonists as novel oral treatment for type 2 diabetes mellitus","volume":"24","author":"Defossa","year":"2014","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2023.115267_bib12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/13543776.2020.1698546","article-title":"Current status of GPR40\/FFAR1 modulators in medicinal chemistry (2016\u20132019): a patent review","volume":"30","author":"Li","year":"2020","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2023.115267_bib13","article-title":"Discovery of a structurally novel, potent, and once-weekly free fatty acid receptor 1 agonist for the treatment of diabetes","volume":"245","author":"Wang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115267_bib14","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1111\/bph.14980","article-title":"HWL-088, a new potent free fatty acid receptor 1 (FFAR1) agonist, improves glucolipid metabolism and acts additively with metformin in ob\/ob diabetic mice","volume":"177","author":"Chen","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115267_bib15","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.ejmech.2019.06.087","article-title":"Design, synthesis and biological evaluation of novel FFA1\/GPR40 agonists: new breakthrough in an old scaffold","volume":"179","author":"Li","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115267_bib16","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ejmech.2018.12.069","article-title":"Discovery of first-in-class thiazole-based dual FFA1\/PPAR\u03b4 agonists as potential anti-diabetic agents","volume":"164","author":"Li","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115267_bib17","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1021\/ml1000855","article-title":"Discovery of TAK-875: a potent, selective, and orally bioavailable GPR40 agonist","volume":"1","author":"Negoro","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115267_bib18","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/dom.12467","article-title":"Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial","volume":"17","author":"Kaku","year":"2015","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejmech.2023.115267_bib19","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1016\/j.bmcl.2008.07.071","article-title":"Physiochemical drug properties associated with in vivo toxicological outcomes","volume":"18","author":"Hughes","year":"2008","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2023.115267_bib20","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1517\/17460441.2012.714363","article-title":"The influence of lipophilicity in drug discovery and design","volume":"7","author":"Arnott","year":"2012","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115267_bib21","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.brainres.2011.11.012","article-title":"Involvement of the long-chain fatty acid receptor GPR40 as a novel pain regulatory system","volume":"1432","author":"Nakamoto","year":"2012","journal-title":"Brain Res."},{"key":"10.1016\/j.ejmech.2023.115267_bib22","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1021\/ml400501x","article-title":"Optimization of GPR40 agonists for type 2 diabetes","volume":"5","author":"Liu","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115267_bib23","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1016\/j.bmcl.2013.03.060","article-title":"Discovery of novel orally bioavailable GPR40 agonists","volume":"23","author":"Lu","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2023.115267_bib24","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1021\/ml4000673","article-title":"Discovery of TUG-770: a highly potent free fatty acid receptor 1 (FFA1\/GPR40) agonist for treatment of type 2 diabetes","volume":"4","author":"Christiansen","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115267_bib25","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1021\/ml500391n","article-title":"Discovery of DS-1558: a potent and orally bioavailable GPR40 agonist","volume":"6","author":"Takano","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115267_bib26","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1021\/acsmedchemlett.8b00213","article-title":"Discovery of AM-6226: a potent and orally bioavailable GPR40 full agonist that displays efficacy in nonhuman primates","volume":"9","author":"Brown","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115267_bib27","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejmech.2018.04.023","article-title":"Design, synthesis and structure activity relationship studies of GPR40 agonists containing amide linker","volume":"152","author":"Chen","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115267_bib28","doi-asserted-by":"crossref","first-page":"5780","DOI":"10.1016\/j.bmc.2018.10.019","article-title":"Design and optimization of 2,3-dihydrobenzo b 1,4 dioxine propanoic acids as novel GPR40 agonists with improved pharmacokinetic and safety profiles","volume":"26","author":"Guo","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115267_bib29","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1021\/acs.jmedchem.7b01411","article-title":"Discovery of LY3104607: a potent and selective G protein-coupled receptor 40 (GPR40) agonist with optimized pharmacokinetic properties to support once daily oral treatment in patients with type 2 diabetes mellitus","volume":"61","author":"Hamdouchi","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115267_bib30","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/j.bmcl.2019.04.050","article-title":"Design, synthesis and biological evaluation of indane derived GPR40 agoPAMs","volume":"29","author":"Pio","year":"2019","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2023.115267_bib31","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1021\/acs.jmedchem.7b00982","article-title":"Discovery of potent and orally bioavailable dihydropyrazole GPR40 agonists","volume":"61","author":"Shi","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115267_bib32","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1016\/j.bmcl.2018.07.048","article-title":"Design, synthesis and biological evaluation of a series of novel GPR40 agonists containing nitrogen heterocyclic rings","volume":"28","author":"Sun","year":"2018","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2023.115267_bib33","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1021\/acs.jmedchem.6b01357","article-title":"Discovery of potent and orally bioavailable GPR40 full agonists bearing thiophen-2-ylpropanoic acid scaffold","volume":"60","author":"Li","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115267_bib34","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1021\/ml300133f","article-title":"Discovery of AM-1638: a potent and orally bioavailable GPR40\/FFA1 full agonist","volume":"3","author":"Brown","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115267_bib35","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1021\/ml4005123","article-title":"Improving the pharmacokinetics of GPR40\/FFA1 full agonists","volume":"5","author":"Du","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115267_bib36","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1021\/acsmedchemlett.8b00444","article-title":"Discovery of a GPR40 superagonist: the impact of aryl propionic acid alpha-fluorination","volume":"10","author":"Huang","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115267_bib37","doi-asserted-by":"crossref","first-page":"10352","DOI":"10.1021\/acs.jmedchem.0c00843","article-title":"Design and identification of a GPR40 full agonist (SCO-267) possessing a 2-carbamoylphenyl piperidine moiety","volume":"63","author":"Furukawa","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115267_bib38","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.2337\/db21-0451","article-title":"SCO-267, a GPR40 full agonist, stimulates islet and gut hormone secretion and improves glycemic control in humans","volume":"70","author":"Nishizaki","year":"2021","journal-title":"Diabetes"},{"key":"10.1016\/j.ejmech.2023.115267_bib39","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/1740774519836766","article-title":"Determination of fasiglifam-induced liver toxicity: insights from the data monitoring committee of the fasiglifam clinical trials program","volume":"16","author":"Shavadia","year":"2019","journal-title":"Clin. Trials"},{"key":"10.1016\/j.ejmech.2023.115267_bib40","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1124\/dmd.115.064121","article-title":"Fasiglifam (TAK-875) inhibits hepatobiliary transporters: a possible factor contributing to fasiglifam-induced liver injury","volume":"43","author":"Li","year":"2015","journal-title":"Drug Metabol. Dispos."},{"key":"10.1016\/j.ejmech.2023.115267_bib41","series-title":"Fasiglifam (TAK-875): Mechanistic Investigation and Retrospective Identification of Hazards for Drug Induced Liver Injury","author":"Otieno","year":"2017"},{"key":"10.1016\/j.ejmech.2023.115267_bib42","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.22345","article-title":"Mechanistic investigations of the liver toxicity of the free fatty acid receptor 1 agonist fasiglifam (TAK875) and its primary metabolites","volume":"33","author":"Ackerson","year":"2019","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"10.1016\/j.ejmech.2023.115267_bib43","first-page":"50","article-title":"Fasiglifam (TAK-875) alters bile acid homeostasis in rats and dogs: a potential cause of drug induced liver injury","volume":"157","author":"Wolenski","year":"2017","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.ejmech.2023.115267_bib44","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1021\/ml300427u","article-title":"Discovery and optimization of potent GPR40 full agonists containing tricyclic spirocycles","volume":"4","author":"Wang","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115267_bib45","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1021\/ml1000855","article-title":"Discovery of TAK-875: a potent, selective, and orally bioavailable GPR40 agonist","volume":"1","author":"Negoro","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115267_bib46","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1021\/acs.jmedchem.6b01559","article-title":"Discovery of pyrrolidine-containing GPR40 agonists: stereochemistry effects a change in binding mode","volume":"60","author":"Jurica","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115267_bib47","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1021\/acs.jcim.2c00417","article-title":"Mechanistic studies on the stereoselectivity of FFAR1 modulators","volume":"62","author":"Teng","year":"2022","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2023.115267_bib48","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ejmech.2017.07.001","article-title":"Discovery of phenylsulfonyl acetic acid derivatives with improved efficacy and safety as potent free fatty acid receptor 1 agonists for the treatment of type 2 diabetes","volume":"138","author":"Li","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115267_bib49","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ejmech.2016.02.040","article-title":"Design, synthesis and Structure-activity relationship studies of new thiazole-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes","volume":"113","author":"Li","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115267_bib50","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1021\/acs.jmedchem.6b01357","article-title":"Discovery of potent and orally bioavailable GPR40 full agonists bearing thiophen-2-ylpropanoic acid scaffold","volume":"60","author":"Li","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115267_bib51","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1021\/jo049758h","article-title":"A facile one-pot synthesis of alkyl aryl sulfides from aryl bromides","volume":"69","author":"Ham","year":"2004","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ejmech.2023.115267_bib52","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.molcata.2006.02.006","article-title":"Effective asymmetric oxidation of enones and alkyl aryl sulfides","volume":"251","author":"Hinch","year":"2006","journal-title":"J. Mol. Catal. Chem."},{"key":"10.1016\/j.ejmech.2023.115267_bib53","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1021\/jm2012968","article-title":"Identification of fused-ring alkanoic acids with improved pharmacokinetic profiles that act as G protein-coupled receptor 40\/free fatty acid receptor 1 agonists","volume":"55","author":"Negoro","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115267_bib54","doi-asserted-by":"crossref","first-page":"7842","DOI":"10.1021\/jo201192c","article-title":"Reduction of amine N-oxides by diboron reagents","volume":"76","author":"Kokatla","year":"2011","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ejmech.2023.115267_bib55","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1021\/jm300170m","article-title":"Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40\/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent","volume":"55","author":"Negoro","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115267_bib56","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1021\/jm301470a","article-title":"Discovery of a potent and selective free fatty acid receptor 1 agonist with low lipophilicity and high oral bioavailability","volume":"56","author":"Christiansen","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115267_bib57","series-title":"(Alkoxyphenyl)hexynoic Acid Derivatives as GPR40 Receptor Activators and Their Preparation and Use for Prevention and Treatment of Diabetes","first-page":"67pp","author":"Keil","year":"2012"},{"key":"10.1016\/j.ejmech.2023.115267_bib58","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/nature13494","article-title":"High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875","volume":"513","author":"Srivastava","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115267_bib59","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41422-022-00680-4","article-title":"Structure of human NTCP reveals the basis of recognition and sodium-driven transport of bile salts into the liver","volume":"32","author":"Liu","year":"2022","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2023.115267_bib60","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/S0022-3565(24)38310-7","article-title":"Use of Ca2+ modulation to evaluate biliary excretion in sandwich-cultured rat hepatocytes","volume":"289","author":"Liu","year":"1999","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2023.115267_bib61","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3109\/03602530903491881","article-title":"Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity","volume":"42","author":"Swift","year":"2010","journal-title":"Drug Metabol. Rev."},{"key":"10.1016\/j.ejmech.2023.115267_bib62","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/aps.2014.65","article-title":"Timosaponin A3 induces hepatotoxicity in rats through inducing oxidative stress and down-regulating bile acid transporters","volume":"35","author":"Wu","year":"2014","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2023.115267_bib63","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1002\/jps.23070","article-title":"Assessment of biliary clearance in early drug discovery using sandwich-cultured hepatocyte model","volume":"101","author":"Pan","year":"2012","journal-title":"J. Pharmaceut. Sci."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423002337?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423002337?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:50:28Z","timestamp":1759330228000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423002337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":62,"alternative-id":["S0223523423002337"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115267","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of orally effective and safe GPR40 agonists by incorporating a chiral, rigid and polar sulfoxide into \u03b2-position to the carboxylic acid","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115267","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115267"}}